Hepatitis C Diagnosis and Treatment Market Research Report - Forecast till 2027

Hepatitis C Diagnosis and Treatment Market Size, Trends and Growth Analysis By Diagnosis (Liver Function Tests, Liver Biopsy, Blood Tests and others), Treatment (Antiviral Medications, Immuno-Modulators, Liver Transplantation and others), End User (Hospitals & Clinics, Diagnostic Centers and others) and Region (Americas, Europe, Asia-Pacific and Middle East & Africa) - Forecast till 2027

ID: MRFR/MED/1040-HCR | February, 2021 | Region : Global

Hepatitis C Diagnosis and Treatment Market Scenario


Hepatitis C Diagnosis and Treatment Market is expected to exhibit significant growth over the forecast period. The market is projected to register a 3.82% CAGR over the forecast period.


Hepatitis C is a liver infection that is caused due to the hepatitis C virus. The hepatitis C virus may cause both acute as well as chronic hepatitis. It is a bloodborne virus and is commonly infected through small quantities of blood.


Factors such as the high prevalence of hepatitis C and increasing awareness regarding the disease are expected to drive the market growth. According to an article published by the World Health Organization (WHO) in July 2019, an estimated 71 million people suffer from chronic hepatitis C virus infection, globally.


However, stringent government regulations and alternate treatment options, such as herbal treatment offered at comparatively lower prices are expected to hamper the Hepatitis C Diagnosis and Treatment Market growth.


Key Players


Hoffmann-La Roche Ltd (Switzerland), Vertex Pharmaceuticals Incorporated (US), Gilead Sciences, Inc. (US), AbbVie Inc. (US), GlaxoSmithKline PLC (UK), Novartis Pharmaceuticals Corporation (Switzerland), Bristol-Myers Squibb Company (US), Abbott (US), Beckman Coulter, Inc. (US), Siemens Medical Solutions USA, Inc. (Germany), MedMira Inc. (Canada), DiaSorin SpA (Italy), Qiagen (Germany), bioMérieux SA (France), Hologic, Inc. (US), and Bio-Rad Laboratories, Inc. (US) are some of the Key Players operating in the Hepatitis C Diagnosis and Treatment Market.


Segmentation


The Hepatitis C Diagnosis and Treatment Market has been segmented into diagnosis, treatment, end-user, and region.


Based on diagnosis, the hepatitis C diagnosis and treatment market has been divided into liver function tests, liver biopsy, blood tests, and others.


The hepatitis C diagnosis and treatment market, by treatment, has been segmented into antiviral medications, immune-modulators, liver transplantation, and others.


The hepatitis C diagnosis and treatment market, by end-user, has been segmented into hospitals & clinics, diagnostic centers, and others.


The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The market in the Americas has further been segmented into North America and Latin America, with the North American market divided into the US and Canada.


The European market has been segmented into Western Europe and Eastern Europe. The market in Western Europe has further been classified into France, Germany, Spain, the UK, Italy, and the rest of Western Europe. 


The hepatitis C diagnosis and treatment market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific.


The Middle East & Africa market has been segmented into the Middle East and Africa.


Regional Market Summary


Global Hepatitis C Diagnosis and Treatment Market Share (%), by Region, 2018  Hepatitis C Diagnosis and Treatment Market


Source: Centers for Disease Control and Prevention (CDC), Eurostat, White Papers, Company Presentations, and Annual Reports


Geographically, the market has been segmented into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas is anticipated to dominate the hepatitis C diagnosis and treatment market owing to the increasing patient population suffering from hepatitis C and presence of major players, such as Vertex Pharmaceuticals Incorporated, AbbVie Inc., Bristol-Myers Squibb Company, Abbott, Beckman Coulter, Inc., Hologic, Inc., and Bio-Rad Laboratories, Inc. in the region. According to a report published by the Centers for Disease Control and Prevention in July 2019, approximately 2.4 million people in the US are suffering from hepatitis C.


Europe is expected to hold the second-largest position in the global market owing to the growing awareness regarding hepatitis C and the rising patient population suffering from the disease. According to the WHO, as of 2018, 14 million people in Europe suffered from hepatitis C.


Asia-Pacific is expected to be the fastest-growing regional market owing to the high patient population suffering from hepatitis C and rising number of initiatives taken by governments as well as private institutes to create awareness regarding hepatitis C. For instance, In June 2015, Abbott launched “LiverHealth”, an initiative to provide easy diagnosis of liver health and to raise awareness regarding hepatitis C in India.


The hepatitis C diagnosis and treatment market in the Middle East & Africa is expected to grow slowly, owing to the rising patient population suffering from hepatitis C. According to the WHO, 10 million people in Africa suffer from chronic viral hepatitis C.


Hepatitis C Diagnosis and Treatment Market, by Diagnosis



  • Liver Function Tests

  • Liver Biopsy

  • Blood Tests

  • Others


Hepatitis C Diagnosis and Treatment Market, by Treatment



  • Antiviral Medications

  • Immuno-Modulators

  • Liver Transplantation

  • Others


Hepatitis C Diagnosis and Treatment Market, by End User



  • Hospitals and Clinics

  • Diagnostic Centers

  • Others


Hepatitis C Diagnosis and Treatment Market, by Region



  • Americas


    • North America


      • US

      • Canada


    • Latin America




  • Europe


    • Western Europe


      • Germany

      • France

      • Italy

      • Spain

      • UK

      • Rest of Western Europe


    • Eastern Europe




  • Asia-Pacific


    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Rest of Asia-Pacific




  • Middle East & Africa


    • Middle East

    • Africa



Intended Audience



  • Biotechnology and Pharmaceutical Companies

  • Research Institutes

  • Medical Device Companies

  • Hospitals and Clinics

  • Ambulatory Surgical Centers

  • Academic Institutes

  • Government Organizations

Table of Contents


REPORT PROLOGUE

MARKET INTRODUCTION


2.1. Definition

2.2. Scope of the Study

2.2.1. Research Objective

2.2.2. Assumptions

2.2.3. Limitations


RESEARCH METHODOLOGY


3.1. Overview

3.2. Primary Research

3.3. Secondary Research

3.4. Market Size Estimation


MARKET DYNAMICS


4.1. Overview

4.2. Drivers

4.3. Restraints

4.4. Opportunities


MARKET FACTOR ANALYSIS


5.1. Porter’s Five Forces Analysis

5.1.1. Bargaining Power of Suppliers

5.1.2. Bargaining Power of Buyers

5.1.3. Threat of New Entrants

5.1.4. Threat of Substitutes

5.1.5. Intensity of Rivalry

5.2. Value Chain Analysis



GLOBAL HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY DIAGNOSIS


6.1. Overview

6.2. Liver Function Tests

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.3. Liver Biopsy

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.4. Blood Tests

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.5. Others

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027


GLOBAL HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY TREATMENT


7.1. Overview

7.2. Antiviral Medications

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.3. Immuno-Modulators

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.4. Liver Transplantation

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.5. Others

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027


GLOBAL HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY END USER


8.1. Overview

8.2. Hospitals and Clinics

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

8.3. Diagnostic Centers

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

8.4. Others

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027


GLOBAL HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY REGION


9.1. Overview

9.2. Americas

9.2.1. North America

9.2.1.1. US

9.2.1.2. Canada

9.2.2. Latin America

9.3. Europe

9.3.1. Western Europe

9.3.1.1. Germany

9.3.1.2. France

9.3.1.3. Italy

9.3.1.4. Spain

9.3.1.5. UK

9.3.1.6. Rest of Western Europe

9.3.2. Eastern Europe

9.4. Asia-Pacific

9.4.1. Japan

9.4.2. China

9.4.3. India

9.4.4. Australia

9.4.5. South Korea

9.4.6. Rest of Asia-Pacific

9.5. Middle East & Africa

9.5.1. Middle East

9.5.2. Africa


COMPANY LANDSCAPE


10.1. Overview

10.2. Competitive Analysis

10.3. Market Share Analysis

10.4. Major Growth Strategy in the Global Hepatitis C Diagnosis and Treatment Market

10.5. Competitive Benchmarking

10.6. Leading Players in Terms of the Number of Developments in the Global Hepatitis C Diagnosis and Treatment Market

10.7. Key Developments and Growth Strategies

10.7.1. Product Launch/Service Deployment

10.7.2. Mergers and Acquisitions

10.7.3. Joint Ventures

10.8. Major Players Financial Matrix & Market Ratio

10.8.1. Sales & Operating Income 2020

10.8.2. Major Players R&D Expenditure 2020

10.9. Major Players Capital Market Ratio


COMPANY PROFILES


11.1. F. Hoffmann-La Roche Ltd

11.1.1. Company Overview

11.1.2. Product Overview

11.1.3. Financial Overview

11.1.4. Key Developments

11.1.5. SWOT Analysis

11.1.6. Key Strategies

11.2. Vertex Pharmaceuticals Incorporated

11.2.1. Company Overview

11.2.2. Product Overview

11.2.3. Financial Overview

11.2.4. Key Developments

11.2.5. SWOT Analysis

11.2.6. Key Strategies

11.3. Gilead Sciences, Inc.

11.3.1. Company Overview

11.3.2. Product Overview

11.3.3. Financial Overview

11.3.4. Key Developments

11.3.5. SWOT Analysis

11.3.6. Key Strategies

11.4. AbbVie Inc.

11.4.1. Company Overview

11.4.2. Product Overview

11.4.3. Financial Overview

11.4.4. Key Developments

11.4.5. SWOT Analysis

11.4.6. Key Strategies

11.5. GlaxoSmithKline plc

11.5.1. Company Overview

11.5.2. Product Overview

11.5.3. Financial Overview

11.5.4. Key Developments

11.5.5. SWOT Analysis

11.5.6. Key Strategies

11.6. Novartis Pharmaceuticals Corporation

11.6.1. Company Overview

11.6.2. Product Overview

11.6.3. Financial Overview

11.6.4. Key Developments

11.6.5. SWOT Analysis

11.6.6. Key Strategies

11.7. Bristol-Myers Squibb Company

11.7.1. Company Overview

11.7.2. Product Overview

11.7.3. Financial Overview

11.7.4. Key Developments

11.7.5. SWOT Analysis

11.7.6. Key Strategies

11.8. Abbott.

11.8.1. Company Overview

11.8.2. Product Overview

11.8.3. Financial Overview

11.8.4. Key Developments

11.8.5. SWOT Analysis

11.8.6. Key Strategies

11.9. Beckman Coulter, Inc.

11.9.1. Company Overview

11.9.2. Product Overview

11.9.3. Financial Overview

11.9.4. Key Developments

11.9.5. SWOT Analysis

11.9.6. Key Strategies

11.10. Siemens Medical Solutions USA, Inc.

11.10.1. Company Overview

11.10.2. Product Overview

11.10.3. Financial Overview

11.10.4. Key Developments

11.10.5. SWOT Analysis

11.10.6. Key Strategies

11.11. MedMira Inc.

11.11.1. Company Overview

11.11.2. Product Overview

11.11.3. Financial Overview

11.11.4. Key Developments

11.11.5. SWOT Analysis

11.11.6. Key Strategies

11.12. DiaSorin SpA

11.12.1. Company Overview

11.12.2. Product Overview

11.12.3. Financial Overview

11.12.4. Key Developments

11.12.5. SWOT Analysis

11.12.6. Key Strategies

11.13. Qiagen

11.13.1. Company Overview

11.13.2. Product Overview

11.13.3. Financial Overview

11.13.4. Key Developments

11.13.5. SWOT Analysis

11.13.6. Key Strategies

11.14. bioMérieux SA

11.14.1. Company Overview

11.14.2. Product Overview

11.14.3. Financial Overview

11.14.4. Key Developments

11.14.5. SWOT Analysis

11.14.6. Key Strategies

11.15. Hologic, Inc.

11.15.1. Company Overview

11.15.2. Product Overview

11.15.3. Financial Overview

11.15.4. Key Developments

11.15.5. SWOT Analysis

11.15.6. Key Strategies

11.16. Bio-Rad Laboratories, Inc.

11.16.1. Company Overview

11.16.2. Product Overview

11.16.3. Financial Overview

11.16.4. Key Developments

11.16.5. SWOT Analysis

11.16.6. Key Strategies

11.17. Others


APPENDIX


12.1. References

12.2. Related Reports


LIST OF TABLES

TABLE 1 GLOBAL HEPATITIS C DIAGNOSIS AND TREATMENT MARKET SYNOPSIS, 2020-2027

TABLE 2 GLOBAL HEPATITIS C DIAGNOSIS AND TREATMENT MARKET ESTIMATES & FORECAST, 2020-2027 (USD MILLION)

TABLE 3 GLOBAL HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY DIAGNOSIS, 2020-2027 (USD MILLION)

TABLE 4 GLOBAL HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY TREATMENT, 2020-2027 (USD MILLION)

TABLE 5 GLOBAL HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 6 GLOBAL HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY REGION, 2020-2027 (USD MILLION)

TABLE 7 NORTH AMERICA: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY DIAGNOSIS, 2020-2027 (USD MILLION)

TABLE 8 NORTH AMERICA: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY TREATMENT, 2020-2027 (USD MILLION)

TABLE 9 NORTH AMERICA: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 10 US: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY DIAGNOSIS, 2020-2027 (USD MILLION)

TABLE 11 US: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY TREATMENT, 2020-2027 (USD MILLION)

TABLE 12 US: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 13 CANADA: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY DIAGNOSIS, 2020-2027 (USD MILLION)

TABLE 14 CANADA: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY TREATMENT, 2020-2027 (USD MILLION)

TABLE 15 CANADA: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 16 LATIN AMERICA: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY DIAGNOSIS, 2020-2027 (USD MILLION)

TABLE 17 LATIN AMERICA: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY TREATMENT, 2020-2027 (USD MILLION)

TABLE 18 LATIN AMERICA: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 19 EUROPE: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY DIAGNOSIS, 2020-2027 (USD MILLION)

TABLE 20 EUROPE: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY TREATMENT, 2020-2027 (USD MILLION)

TABLE 21 EUROPE: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 22 WESTERN EUROPE: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY DIAGNOSIS, 2020-2027 (USD MILLION)

TABLE 23 WESTERN EUROPE: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY TREATMENT, 2020-2027 (USD MILLION)

TABLE 24 WESTERN EUROPE: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 25 EASTERN EUROPE: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY DIAGNOSIS, 2020-2027 (USD MILLION)

TABLE 26 EASTERN EUROPE: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY TREATMENT, 2020-2027 (USD MILLION)

TABLE 27 EASTERN EUROPE: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 28 ASIA-PACIFIC: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY DIAGNOSIS, 2020-2027 (USD MILLION)

TABLE 29 ASIA-PACIFIC: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY TREATMENT, 2020-2027 (USD MILLION)

TABLE 30 ASIA-PACIFIC: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 31 MIDDLE EAST & AFRICA: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY DIAGNOSIS, 2020-2027 (USD MILLION)

TABLE 32 MIDDLE EAST & AFRICA: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY TREATMENT, 2020-2027 (USD MILLION)

TABLE 33 MIDDLE EAST & AFRICA: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET, BY END USER, 2020-2027 (USD MILLION)


LIST OF FIGURES

FIGURE 1 RESEARCH PROCESS

FIGURE 2 MARKET STRUCTURE FOR THE GLOBAL HEPATITIS C DIAGNOSIS AND TREATMENT MARKET

FIGURE 3 MARKET DYNAMICS FOR THE GLOBAL HEPATITIS C DIAGNOSIS AND TREATMENT MARKET

FIGURE 4 GLOBAL HEPATITIS C DIAGNOSIS AND TREATMENT MARKET SHARE, BY DIAGNOSIS, 2020 (%)

FIGURE 5 GLOBAL HEPATITIS C DIAGNOSIS AND TREATMENT MARKET SHARE, BY TREATMENT TYPE, 2020 (%)

FIGURE 6 GLOBAL HEPATITIS C DIAGNOSIS AND TREATMENT MARKET SHARE, BY END USER, 2020 (%)

FIGURE 7 GLOBAL HEPATITIS C DIAGNOSIS AND TREATMENT MARKET SHARE, BY REGION, 2020 (%)

FIGURE 7 AMERICAS: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET SHARE BY REGION, 2020 (%)

FIGURE 8 NORTH AMERICA: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET SHARE, BY COUNTRY, 2020 (%)

FIGURE 9 EUROPE: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET SHARE, BY REGION, 2020 (%)

FIGURE 10 WESTERN EUROPE: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET SHARE, BY COUNTRY, 2020 (%)

FIGURE 11 ASIA-PACIFIC: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET SHARE, BY COUNTRY, 2020 (%)

FIGURE 12 MIDDLE EAST & AFRICA: HEPATITIS C DIAGNOSIS AND TREATMENT MARKET SHARE, BY COUNTRY, 2020 (%)

FIGURE 13 GLOBAL HEPATITIS C DIAGNOSIS AND TREATMENT MARKET: COMPANY SHARE ANALYSIS, 2020 (%)

FIGURE 14 F. HOFFMANN-LA ROCHE LTD.: KEY FINANCIALS

FIGURE 15 F. HOFFMANN-LA ROCHE LTD: SEGMENTAL REVENUE

FIGURE 16 F. HOFFMANN-LA ROCHE LTD: REGIONAL REVENUE

FIGURE 17 VERTEX PHARMACEUTICALS INCORPORATED: KEY FINANCIALS

FIGURE 18 VERTEX PHARMACEUTICALS INCORPORATED: SEGMENTAL REVENUE

FIGURE 19 VERTEX PHARMACEUTICALS INCORPORATED: REGIONAL REVENUE

FIGURE 20 GILEAD SCIENCES, INC.: KEY FINANCIALS

FIGURE 21 GILEAD SCIENCES, INC.: SEGMENTAL REVENUE

FIGURE 22 GILEAD SCIENCES, INC.: REGIONAL REVENUE

FIGURE 23 ABBVIE INC.: KEY FINANCIALS

FIGURE 24 ABBVIE INC.: SEGMENTAL REVENUE

FIGURE 25 ABBVIE INC.: REGIONAL REVENUE

FIGURE 26 GLAXOSMITHKLINE PLC: KEY FINANCIALS

FIGURE 27 GLAXOSMITHKLINE PLC: SEGMENTAL REVENUE

FIGURE 28 GLAXOSMITHKLINE PLC: REGIONAL REVENUE

FIGURE 29 NOVARTIS PHARMACEUTICALS CORPORATION: KEY FINANCIALS

FIGURE 30 NOVARTIS PHARMACEUTICALS CORPORATION: SEGMENTAL REVENUE

FIGURE 31 NOVARTIS PHARMACEUTICALS CORPORATION: REGIONAL REVENUE

FIGURE 32 BRISTOL-MYERS SQUIBB COMPANY: KEY FINANCIALS

FIGURE 33 BRISTOL-MYERS SQUIBB COMPANY: SEGMENTAL REVENUE

FIGURE 34 BRISTOL-MYERS SQUIBB COMPANY: REGIONAL REVENUE

FIGURE 35 ABBOTT.: KEY FINANCIALS

FIGURE 36 ABBOTT.: SEGMENTAL REVENUE

FIGURE 37 ABBOTT.: REGIONAL REVENUE

FIGURE 38 BECKMAN COULTER, INC.: KEY FINANCIALS

FIGURE 39 BECKMAN COULTER, INC.: SEGMENTAL REVENUE

FIGURE 40 BECKMAN COULTER, INC.: REGIONAL REVENUE

FIGURE 41 SIEMENS MEDICAL SOLUTIONS USA, INC.: KEY FINANCIALS

FIGURE 42 SIEMENS MEDICAL SOLUTIONS USA, INC.: SEGMENTAL REVENUE

FIGURE 43 SIEMENS MEDICAL SOLUTIONS USA, INC.: REGIONAL REVENUE

FIGURE 44 MEDMIRA INC.: KEY FINANCIALS

FIGURE 45 MEDMIRA INC.: SEGMENTAL REVENUE

FIGURE 46 MEDMIRA INC.: REGIONAL REVENUE

FIGURE 47 DIASORIN S.P.A.: KEY FINANCIALS

FIGURE 48 DIASORIN S.P.A.: SEGMENTAL REVENUE

FIGURE 49 DIASORIN S.P.A.: REGIONAL REVENUE

FIGURE 50 QIAGEN: KEY FINANCIALS

FIGURE 51 QIAGEN: SEGMENTAL REVENUE

FIGURE 52 QIAGEN: REGIONAL REVENUE

FIGURE 53 BIOMÉRIEUX SA: KEY FINANCIALS

FIGURE 54 BIOMÉRIEUX SA: SEGMENTAL REVENUE

FIGURE 55 BIOMÉRIEUX SA: REGIONAL REVENUE

FIGURE 56 HOLOGIC, INC.: KEY FINANCIALS

FIGURE 57 HOLOGIC, INC.: SEGMENTAL REVENUE

FIGURE 58 HOLOGIC, INC.: REGIONAL REVENUE

FIGURE 59 BIO-RAD LABORATORIES, INC.: KEY FINANCIALS

FIGURE 60 BIO-RAD LABORATORIES, INC.: SEGMENTAL REVENUE

FIGURE 61 BIO-RAD LABORATORIES, INC.: REGIONAL REVENUE